Taxane resistance in breast cancer: A closed HER2 circuit?

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1825, Issue 2, 2012, Pages 197-206

  de Hoon, Joep P J ^a,b   Veeck, Jürgen ^a,b   Vriens, Birgit E P J ^a,b   Calon, Tim G A ^a,b   van Engeland, Manon ^a,b   Tjan Heijnen, Vivianne C G ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Breast cancer; Docetaxel; Drug resistance; HER2 signaling; Paclitaxel; Taxanes

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; Y BOX BINDING PROTEIN 1;

APOPTOSIS; BREAST CANCER; CANCER RESISTANCE; CELL SURVIVAL; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSPORT; GENE MUTATION; HUMAN; MICROTUBULE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84856435959     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.01.001     Document Type: Review

References (163)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
3. Amar S., Roy V., Perez E. Treatment of metastatic breast cancer: looking towards the future. Breast Cancer Res. Treat. 2009, 114:413-422.
4. De Laurentiis M., Cancello G., D'Agostino D., Giuliano M., Giordano A., Montagna E., Lauria R., Forestieri V., Esposito A., Silvestro L., Pennacchio R., Criscitiello C., Montanino A., Limite G., Bianco A.R., De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 2008, 26:44-53.
5. Saloustros E., Mavroudis D., Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert. Opin. Pharmacother. 2008, 9:2603-2616.
6. Weber B.L., Vogel C., Jones S., Harvey H., Hutchins L., Bigley J., Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J. Clin. Oncol. 1995, 13:2722-2730.
7. Robert N., Leyland-Jones B., Asmar L., Belt R., Ilegbodu D., Loesch D., Raju R., Valentine E., Sayre R., Cobleigh M., Albain K., McCullough C., Fuchs L., Slamon D. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer. J. Clin. Oncol. 2006, 24:2786-2792.
8. Chan S., Friedrichs K., Noel D., Pinter T., Van Belle S., Vorobiof D., Duarte R., Gil Gil M., Bodrogi I., Murray E., Yelle L., von Minckwitz G., Korec S., Simmonds P., Buzzi F., Gonzalez Mancha R., Richardson G., Walpole E., Ronzoni M., Murawsky M., Alakl M., Riva A., Crown J. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17:2341-2354.
9. Paridaens R., Biganzoli L., Bruning P., Klijn J.G., Gamucci T., Houston S., Coleman R., Schachter J., Van Vreckem A., Sylvester R., Awada A., Wildiers J., Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J. Clin. Oncol. 2000, 18:724-733.
10. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., Wood W.C. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial. J. Clin. Oncol. 2003, 21:588-592.
11. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents 2002, 2:1-17.
12. Ringel I., Horwitz S.B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst. 1991, 83:288-291.
13. Valero V., Jones S.E., Von Hoff D.D., Booser D.J., Mennel R.G., Ravdin P.M., Holmes F.A., Rahman Z., Schottstaedt M.W., Erban J.K., Esparza-Guerra L., Earhart R.H., Hortobagyi G.N., Burris H.A. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J. Clin. Oncol. 1998, 16:3362-3368.
14. Nicoletti M.I., Lucchini V., D'Incalci M., Giavazzi R. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur. J. Cancer 1994, 30A:691-696.
15. Riou J.F., Naudin A., Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Commun. 1992, 187:164-170.
16. Sato S., Kigawa J., Kanamori Y., Itamochi H., Oishi T., Shimada M., Iba T., Naniwa J., Uegaki K., Terakawa N. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells. Cancer Chemother. Pharmacol. 2004, 53:247-252.
17. Vogel M., Hilsenbeck S.G., Depenbrock H., Danhauser-Riedl S., Block T., Nekarda H., Fellbaum C., Aapro M.S., Bissery M.C., Rastetter J., et al. Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur. J. Cancer 1993, 29A:2009-2014.
18. Bonfoco E., Ceccatelli S., Manzo L., Nicotera P. Colchicine induces apoptosis in cerebellar granule cells. Exp. Cell Res. 1995, 218:189-200.
19. Huschtscha L.I., Bartier W.A., Ross C.E., Tattersall M.H. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br. J. Cancer 1996, 73:54-60.
20. Kawamura K.I., Grabowski D., Weizer K., Bukowski R., Ganapathi R. Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Br. J. Cancer 1996, 73:183-188.
21. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334:1-6.
22. Tishler R.B., Lamppu D.M., Park S., Price B.D. Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res. 1995, 55:6021-6025.
23. Wahl A.F., Donaldson K.L., Fairchild C., Lee F.Y., Foster S.A., Demers G.W., Galloway D.A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med. 1996, 2:72-79.
24. Blagosklonny M.V., Schulte T.W., Nguyen P., Mimnaugh E.G., Trepel J., Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 1995, 55:4623-4626.
25. Haldar S., Chintapalli J., Croce C.M. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996, 56:1253-1255.
26. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
27. Kersting C., Tidow N., Schmidt H., Liedtke C., Neumann J., Boecker W., van Diest P.J., Brandt B., Buerger H. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab. Invest. 2004, 84:582-587.
28. Nagai M.A., Marques L.A., Torloni H., Brentani M.M. Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 1993, 50:412-417.
29. de Munck L., Schaapveld M., Siesling S., Wesseling J., Voogd A.C., Tjan-Heijnen V.C., Otter R., Willemse P.H. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands. Breast Cancer Res. Treat. 2010, 129:229-233.
30. Azambuja E., Durbecq V., Rosa D.D., Colozza M., Larsimont D., Piccart-Gebhart M., Cardoso F. HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann. Oncol. 2008, 19:223-232.
31. Ciardiello F., Caputo R., Pomatico G., De Laurentiis M., De Placido S., Bianco A.R., Tortora G. Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int. J. Cancer 2000, 85:710-715.
32. Yu D., Liu B., Jing T., Sun D., Price J.E., Singletary S.E., Ibrahim N., Hortobagyi G.N., Hung M.C. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 1998, 16:2087-2094.
33. O'Brien C., Cavet G., Pandita A., Hu X., Haydu L., Mohan S., Toy K., Rivers C.S., Modrusan Z., Amler L.C., Lackner M.R. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res. 2008, 68:5380-5389.
34. Modi S., DiGiovanna M.P., Lu Z., Moskowitz C., Panageas K.S., Van Poznak C., Hudis C.A., Norton L., Tan L., Stern D.F., Carter D., Seidman A.D. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 2005, 23:483-487.
35. Van Poznak C., Tan L., Panageas K.S., Arroyo C.D., Hudis C., Norton L., Seidman A.D. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J. Clin. Oncol. 2002, 20:2319-2326.
36. Tan M., Jing T., Lan K.H., Neal C.L., Li P., Lee S., Fang D., Nagata Y., Liu J., Arlinghaus R., Hung M.C., Yu D. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol. Cell 2002, 9:993-1004.
37. Knuefermann C., Lu Y., Liu B., Jin W., Liang K., Wu L., Schmidt M., Mills G.B., Mendelsohn J., Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22:3205-3212.
38. Witters L.M., Santala S.M., Engle L., Chinchilli V., Lipton A. Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. Am. J. Clin. Oncol. 2003, 26:50-54.
39. Yu D., Liu B., Tan M., Li J., Wang S.S., Hung M.C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996, 13:1359-1365.
40. Ueno N.T., Bartholomeusz C., Herrmann J.L., Estrov Z., Shao R., Andreeff M., Price J., Paul R.W., Anklesaria P., Yu D., Hung M.C. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin. Cancer Res. 2000, 6:250-259.
41. Zhang L., Lau Y.K., Xia W., Hortobagyi G.N., Hung M.C. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin. Cancer Res. 1999, 5:343-353.
42. Citri A., Skaria K.B., Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell Res. 2003, 284:54-65.
43. Lu J., Tan M., Huang W.C., Li P., Guo H., Tseng L.M., Su X.H., Yang W.T., Treekitkarnmongkol W., Andreeff M., Symmans F., Yu D. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin. Cancer Res. 2009, 15:1326-1334.
44. Wang S., Huang X., Lee C.K., Liu B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 2010, 29:4225-4236.
45. Ro J., Sahin A., Ro J.Y., Fritsche H., Hortobagyi G., Blick M. Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum. Pathol. 1990, 21:787-791.
46. Sanfilippo O., Ronchi E., De Marco C., Di Fronzo G., Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur. J. Cancer 1991, 27:155-158.
47. Verrelle P., Meissonnier F., Fonck Y., Feillel V., Dionet C., Kwiatkowski F., Plagne R., Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J. Natl. Cancer Inst. 1991, 83:111-116.
48. Wallner J., Depisch D., Hopfner M., Haider K., Spona J., Ludwig H., Pirker R. MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur. J. Cancer 1991, 27:1352-1355.
49. Iseri O.D., Kars M.D., Gunduz U. Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern. Mol. Biol. Rep. 2010, (Electronic publication ahead of print). doi:10.1007/s11033-011-1123-5.
50. McDonald S.L., Stevenson D.A., Moir S.E., Hutcheon A.W., Haites N.E., Heys S.D., Schofield A.C. Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. Eur. J. Cancer 2005, 41:1086-1094.
51. Mechetner E., Kyshtoobayeva A., Zonis S., Kim H., Stroup R., Garcia R., Parker R.J., Fruehauf J.P. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin. Cancer Res. 1998, 4:389-398.
52. Kool M., van der Linden M., de Haas M., Scheffer G.L., de Vree J.M., Smith A.J., Jansen G., Peters G.J., Ponne N., Scheper R.J., Elferink R.P., Baas F., Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6914-6919.
53. Zeng H., Bain L.J., Belinsky M.G., Kruh G.D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res. 1999, 59:5964-5967.
54. Shukla A., Hillegass J.M., MacPherson M.B., Beuschel S.L., Vacek P.M., Pass H.I., Carbone M., Testa J.R., Mossman B.T. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol. Cancer 2010, 9:314.
55. Yang Z., Barnes C.J., Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin. Cancer Res. 2004, 10:3621-3628.
56. Chung J., Uchida E., Grammer T.C., Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol. 1997, 17:6508-6516.
57. Huisman M.T., Chhatta A.A., van Tellingen O., Beijnen J.H., Schinkel A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 2005, 116:824-829.
58. Naramoto H., Uematsu T., Uchihashi T., Doto R., Matsuura T., Usui Y., Uematsu S., Li X., Takahashi M., Yamaoka M., Furusawa K. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int. J. Oncol. 2007, 30:393-401.
59. Shakunthala N. New cytochrome P450 mechanisms: implications for understanding molecular basis for drug toxicity at the level of the cytochrome. Expert Opin. Drug Metab. Toxicol. 2010, 6:1-15.
60. Gilbert L., Elwood L.J., Merino M., Masood S., Barnes R., Steinberg S.M., Lazarous D.F., Pierce L., d'Angelo T., Moscow J.A., et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J. Clin. Oncol. 1993, 11:49-58.
61. Huang J., Tan P.H., Thiyagarajan J., Bay B.H. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod. Pathol. 2003, 16:558-565.
62. Silvestrini R., Veneroni S., Benini E., Daidone M.G., Luisi A., Leutner M., Maucione A., Kenda R., Zucali R., Veronesi U. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J. Natl. Cancer Inst. 1997, 89:639-645.
63. Su F., Hu X., Jia W., Gong C., Song E., Hamar P. Glutathion S transferase pi indicates chemotherapy resistance in breast cancer. J. Surg. Res. 2003, 113:102-108.
64. Coles B.F., Kadlubar F.F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?. Biofactors 2003, 17:115-130.
65. Perquin M., Oster T., Maul A., Froment N., Untereiner M., Bagrel D. The glutathione-related detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues. Cancer Lett. 2000, 158:7-16.
66. Moskaluk C.A., Duray P.H., Cowan K.H., Linehan M., Merino M.J. Immunohistochemical expression of pi-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate. Cancer 1997, 79:1595-1599.
67. Herrmann J.L., Bruckheimer E., McDonnell T.J. Cell death signal transduction and Bcl-2 function. Biochem. Soc. Trans. 1996, 24:1059-1065.
68. Iwao-Koizumi K., Matoba R., Ueno N., Kim S.J., Ando A., Miyoshi Y., Maeda E., Noguchi S., Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 2005, 23:422-431.
69. Arai T., Miyoshi Y., Kim S.J., Akazawa K., Maruyama N., Taguchi T., Tamaki Y., Noguchi S. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur. J. Surg. Oncol. 2008, 34:734-738.
70. Schmidt M., Bachhuber A., Victor A., Steiner E., Mahlke M., Lehr H.A., Pilch H., Weikel W., Knapstein P.G. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J. Cancer Res. Clin. Oncol. 2003, 129:295-302.
71. Miyoshi Y., Taguchi T., Kim S.J., Tamaki Y., Noguchi S. Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancers. Breast Cancer 2005, 12:11-15.
72. Miyoshi Y., Ando A., Takamura Y., Taguchi T., Tamaki Y., Noguchi S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int. J. Cancer 2002, 97:129-132.
73. Amirimani B., Ning B., Deitz A.C., Weber B.L., Kadlubar F.F., Rebbeck T.R. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 2003, 42:299-305.
74. Schirmer M., Toliat M.R., Haberl M., Suk A., Kamdem L.K., Klein K., Brockmoller J., Nurnberg P., Zanger U.M., Wojnowski L. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenet. Genomics 2006, 16:59-71.
75. Tran A., Jullien V., Alexandre J., Rey E., Rabillon F., Girre V., Dieras V., Pons G., Goldwasser F., Treluyer J.M. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin. Pharmacol. Ther. 2006, 79:570-580.
76. Kallio M.J., Nieminen M., Eriksson J.E. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J. 2001, 15:2721-2723.
77. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
78. Asanuma H., Torigoe T., Kamiguchi K., Hirohashi Y., Ohmura T., Hirata K., Sato M., Sato N. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005, 65:11018-11025.
79. Ryan B.M., Konecny G.E., Kahlert S., Wang H.J., Untch M., Meng G., Pegram M.D., Podratz K.C., Crown J., Slamon D.J., Duffy M.J. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann. Oncol. 2006, 17:597-604.
80. Xia W., Bisi J., Strum J., Liu L., Carrick K., Graham K.M., Treece A.L., Hardwicke M.A., Dush M., Liao Q., Westlund R.E., Zhao S., Bacus S., Spector N.L. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 2006, 66:1640-1647.
81. Bieche I., Onody P., Tozlu S., Driouch K., Vidaud M., Lidereau R. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int. J. Cancer 2003, 106:758-765.
82. deFazio A., Chiew Y.E., Sini R.L., Janes P.W., Sutherland R.L. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 2000, 87:487-498.
83. Yu D., Jing T., Liu B., Yao J., Tan M., McDonnell T.J., Hung M.C. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell 1998, 2:581-591.
84. Hawthorne V.S., Huang W.C., Neal C.L., Tseng L.M., Hung M.C., Yu D. ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol. Cancer Res. 2009, 7:592-600.
85. Karni R., Jove R., Levitzki A. Inhibition of pp 60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999, 18:4654-4662.
86. Schmidt M., Lu Y., Liu B., Fang M., Mendelsohn J., Fan Z. Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene 2000, 19:2423-2429.
87. Debernardis D., Sire E.G., De Feudis P., Vikhanskaya F., Valenti M., Russo P., Parodi S., D'Incalci M., Broggini M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 1997, 57:870-874.
88. Fan S., Cherney B., Reinhold W., Rucker K., O'Connor P.M. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin. Cancer Res. 1998, 4:1047-1054.
89. Gan Y., Wientjes M.G., Schuller D.E., Au J.L. Pharmacodynamics of taxol in human head and neck tumors. Cancer Res. 1996, 56:2086-2093.
90. Vasey P.A., Jones N.A., Jenkins S., Dive C., Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol. Pharmacol. 1996, 50:1536-1540.
91. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornace A.J., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., Paull K.D. An information-intensive approach to the molecular pharmacology of cancer. Science 1997, 275:343-349.
92. Kandioler-Eckersberger D., Ludwig C., Rudas M., Kappel S., Janschek E., Wenzel C., Schlagbauer-Wadl H., Mittlbock M., Gnant M., Steger G., Jakesz R. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin. Cancer Res. 2000, 6:50-56.
93. Giannakakou P., Poy G., Zhan Z., Knutsen T., Blagosklonny M.V., Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000, 19:3078-3085.
94. Lanni J.S., Lowe S.W., Licitra E.J., Liu J.O., Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9679-9683.
95. Gurnani M., Lipari P., Dell J., Shi B., Nielsen L.L. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 1999, 44:143-151.
96. Nielsen L.L., Lipari P., Dell J., Gurnani M., Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin. Cancer Res. 1998, 4:835-846.
97. Chadderton A., Villeneuve D.J., Gluck S., Kirwan-Rhude A.F., Gannon B.R., Blais D.E., Parissenti A.M. Role of specific apoptotic pathways in the restoration of paclitaxel-induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells. Breast Cancer Res. Treat. 2000, 59:231-244.
98. Oldham E.A., Li C., Ke S., Wallace S., Huang P. Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int. J. Oncol. 2000, 16:125-132.
99. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J. Clin. Oncol. 1999, 17:1061-1070.
100. Janz M., Harbeck N., Dettmar P., Berger U., Schmidt A., Jurchott K., Schmitt M., Royer H.D. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer 2002, 97:278-282.
101. Bargou R.C., Jurchott K., Wagener C., Bergmann S., Metzner S., Bommert K., Mapara M.Y., Winzer K.J., Dietel M., Dorken B., Royer H.D. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat. Med. 1997, 3:447-450.
102. Rubinstein D.B., Stortchevoi A., Boosalis M., Ashfaq R., Guillaume T. Overexpression of DNA-binding protein B gene product in breast cancer as detected by in vitro-generated combinatorial human immunoglobulin libraries. Cancer Res. 2002, 62:4985-4991.
103. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10869-10874.
104. Lee C., Dhillon J., Wang M.Y., Gao Y., Hu K., Park E., Astanehe A., Hung M.C., Eirew P., Eaves C.J., Dunn S.E. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008, 68:8661-8666.
105. Stratford A.L., Fry C.J., Desilets C., Davies A.H., Cho Y.Y., Li Y., Dong Z., Berquin I.M., Roux P.P., Dunn S.E. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008, 10:R99.
106. Stratford A.L., Habibi G., Astanehe A., Jiang H., Hu K., Park E., Shadeo A., Buys T.P., Lam W., Pugh T., Marra M., Nielsen T.O., Klinge U., Mertens P.R., Aparicio S., Dunn S.E. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res. 2007, 9:R61.
107. Sutherland B.W., Kucab J., Wu J., Lee C., Cheang M.C., Yorida E., Turbin D., Dedhar S., Nelson C., Pollak M., Leighton Grimes H., Miller K., Badve S., Huntsman D., Blake-Gilks C., Chen M., Pallen C.J., Dunn S.E. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005, 24:4281-4292.
108. Wu J., Lee C., Yokom D., Jiang H., Cheang M.C., Yorida E., Turbin D., Berquin I.M., Mertens P.R., Iftner T., Gilks C.B., Dunn S.E. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006, 66:4872-4879.
109. Evdokimova V., Tognon C., Ng T., Ruzanov P., Melnyk N., Fink D., Sorokin A., Ovchinnikov L.P., Davicioni E., Triche T.J., Sorensen P.H. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009, 15:402-415.
110. Habibi G., Leung S., Law J.H., Gelmon K., Masoudi H., Turbin D., Pollak M., Nielsen T.O., Huntsman D., Dunn S.E. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008, 10:R86.
111. Chatterjee M., Rancso C., Stuhmer T., Eckstein N., Andrulis M., Gerecke C., Lorentz H., Royer H.D., Bargou R.C. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008, 111:3714-3722.
112. To K., Fotovati A., Reipas K.M., Law J.H., Hu K., Wang J., Astanehe A., Davies A.H., Lee L., Stratford A.L., Raouf A., Johnson P., Berquin I.M., Royer H.D., Eaves C.J., Dunn S.E. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70:2840-2851.
113. Finkbeiner M.R., Astanehe A., To K., Fotovati A., Davies A.H., Zhao Y., Jiang H., Stratford A.L., Shadeo A., Boccaccio C., Comoglio P., Mertens P.R., Eirew P., Raouf A., Eaves C.J., Dunn S.E. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009, 28:1421-1431.
114. Berquin I.M., Pang B., Dziubinski M.L., Scott L.M., Chen Y.Q., Nolan G.P., Ethier S.P. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005, 24:3177-3186.
115. Ganguly A., Cabral F. New insights into mechanisms of resistance to microtubule inhibitors. Biochim. Biophys. Acta 2011, 1816:164-171.
116. Brooks T.A., Minderman H., O'Loughlin K.L., Pera P., Ojima I., Baer M.R., Bernacki R.J. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther. 2003, 2:1195-1205.
117. Duffy A., Kummar S. Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Target. Oncol. 2009, 4:267-273.
118. Wang T.H., Wang H.S., Ichijo H., Giannakakou P., Foster J.S., Fojo T., Wimalasena J. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem. 1998, 273:4928-4936.
119. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., Pincus M.R., Sardana M., Henderson C.J., Wolf C.R., Davis R.J., Ronai Z. Regulation of JNK signaling by GSTp. EMBO J. 1999, 18:1321-1334.
120. Bernardini S., Bernassola F., Cortese C., Ballerini S., Melino G., Motti C., Bellincampi L., Iori R., Federici G. Modulation of GST P1-1 activity by polymerization during apoptosis. J. Cell. Biochem. 2000, 77:645-653.
121. Shim J., Lee H., Park J., Kim H., Choi E.J. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996, 381:804-806.
122. J.M.T. Berg, J.L. Stryer, L., Biochemistry, 5th ed., Michelle, J., New York, 2001.
123. Marre F., Sanderink G.J., de Sousa G., Gaillard C., Martinet M., Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 1996, 56:1296-1302.
124. Royer I., Monsarrat B., Sonnier M., Wright M., Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 1996, 56:58-65.
125. Engels F.K., Ten Tije A.J., Baker S.D., Lee C.K., Loos W.J., Vulto A.G., Verweij J., Sparreboom A. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther. 2004, 75:448-454.
126. Engels F.K., Loos W.J., Mathot R.A., van Schaik R.H., Verweij J. Influence of ketoconazole on the fecal and urinary disposition of docetaxel. Cancer Chemother. Pharmacol. 2007, 60:569-579.
127. Park J.S., Yamamoto W., Sekikawa T., Matsukawa M., Okamoto R., Sasaki M., Ukon K., Tanimoto K., Kumazaki T., Nishiyama M. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. Int. J. Oncol. 2002, 20:333-338.
128. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., Reed J.C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998, 58:5315-5320.
129. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3:46-54.
130. Tan M., Li P., Klos K.S., Lu J., Lan K.H., Nagata Y., Fang D., Jing T., Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res. 2005, 65:1858-1867.
131. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
132. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
133. Haldar S., Basu A., Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997, 57:229-233.
134. Blagosklonny M.V., Giannakakou P., El-Deiry W.S., Kingston D.G., Higgs P.I., Neckers L., Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 1997, 57:130-135.
135. Poruchynsky M.S., Wang E.E., Rudin C.M., Blagosklonny M.V., Fojo T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 1998, 58:3331-3338.
136. Wang S., Wang Z., Boise L., Dent P., Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem. Biophys. Res. Commun. 1999, 259:67-72.
137. Yamamoto K., Ichijo H., Korsmeyer S.J. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. 1999, 19:8469-8478.
138. Basu A., Haldar S. Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int. J. Oncol. 1998, 13:659-664.
139. Britten R.A., Klein K. Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel. Anticancer Drugs 2000, 11:439-443.
140. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51:6304-6311.
141. Lowe S.W., Bodis S., Bardeesy N., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Jacks T., Pelletier J., Housman D.E. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harb. Symp. Quant. Biol. 1994, 59:419-426.
142. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
143. Tao L., Roberts A.L., Dunphy K.A., Bigelow C., Yan H., Jerry D.J. Repression of mammary stem/progenitor cells by p53 is mediated by notch and separable from apoptotic activity. Stem Cells 2010, 29:119-127.
144. Cross S.M., Sanchez C.A., Morgan C.A., Schimke M.K., Ramel S., Idzerda R.L., Raskind W.H., Reid B.J. A p53-dependent mouse spindle checkpoint. Science 1995, 267:1353-1356.
145. Fukasawa K., Choi T., Kuriyama R., Rulong S., Vande Woude G.F. Abnormal centrosome amplification in the absence of p53. Science 1996, 271:1744-1747.
146. Woods C.M., Zhu J., McQueney P.A., Bollag D., Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med. 1995, 1:506-526.
147. Jurchott K., Bergmann S., Stein U., Walther W., Janz M., Manni I., Piaggio G., Fietze E., Dietel M., Royer H.D. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J. Biol. Chem. 2003, 278:27988-27996.
148. Bergmann S., Royer-Pokora B., Fietze E., Jurchott K., Hildebrandt B., Trost D., Leenders F., Claude J.C., Theuring F., Bargou R., Dietel M., Royer H.D. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res. 2005, 65:4078-4087.
149. Kohno K., Izumi H., Uchiumi T., Ashizuka M., Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003, 25:691-698.
150. Fujii T., Kawahara A., Basaki Y., Hattori S., Nakashima K., Nakano K., Shirouzu K., Kohno K., Yanagawa T., Yamana H., Nishio K., Ono M., Kuwano M., Kage M. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008, 68:1504-1512.
151. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L.A., Ragaz J., Gown A.M., Gilks C.B., van de Rijn M., Perou C.M. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10:5367-5374.
152. Davies A.H., Dunn S.E. YB-1 drives preneoplastic progression: insight into opportunities for cancer prevention. Oncotarget 2011, 2:401-406.
153. Ohga T., Uchiumi T., Makino Y., Koike K., Wada M., Kuwano M., Kohno K. Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 1998, 273:5997-6000.
154. Bader A.G., Vogt P.K. Phosphorylation by Akt disables the anti-oncogenic activity of YB-1. Oncogene 2008, 27:1179-1182.
155. Evdokimova V., Ruzanov P., Anglesio M.S., Sorokin A.V., Ovchinnikov L.P., Buckley J., Triche T.J., Sonenberg N., Sorensen P.H. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol. Cell. Biol. 2006, 26:277-292.
156. Davies A.H., Barrett I., Pambid M.R., Hu K., Stratford A.L., Freeman S., Berquin I.M., Pelech S., Hieter P., Maxwell C., Dunn S.E. YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification. Oncogene 2011, 30:3649-3660.
157. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., Wong H., Rosen J., Chang J.C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
158. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008, 10:R25.
159. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:3983-3988.
160. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A.B., Karlsson P., Tange U.B., Sorensen P.G., Moller S., Bergh J., Langkjer S.T. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J. Clin. Oncol. 2011, 29:264-271.
161. Inoue K., Nakagami K., Mizutani M., Hozumi Y., Fujiwara Y., Masuda N., Tsukamoto F., Saito M., Miura S., Eguchi K., Shinkai T., Ando M., Watanabe T., Ohashi Y., Sano M., Noguchi S. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res. Treat. 2011, 119:127-136.
162. Perez E.A., Suman V.J., Davidson N.E., Gralow J.R., Kaufman P.A., Visscher D.W., Chen B., Ingle J.N., Dakhil S.R., Zujewski J., Moreno-Aspitia A., Pisansky T.M., Jenkins R.B. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 2011, 29:4491-4497.
163. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 2011, 366:109-119.